Could CTCs and tumor DNA be more sensitive than a BM aspirate to assess treatment response in MM?

During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, could circulating tumor cells (CTCs) and tumor DNA be more sensitive than a bone marrow (BM) aspirate to assess treatment response in MM?

In this video, Paiva discusses the importance of assessing treatment efficacy in myeloma. He also mentions minimal residual disease (MRD) assessments, next-generation sequencing (NGS) and next-generation flow (NGF).

• #people_blogs
• #ash
• #ash21
• #myeloma
• #tumour